Andrés Bratt-Leal PhD

Dr. Andrés Bratt-Leal is the Co Founder and Senior Vice President of Research at Aspen Neuroscience, where he leads the research team developing personalized iPSC derived cell therapies for Parkinson's disease and continues to drive innovation in stem cell engineering and AI enabled genomic quality control. Aspen's lead program, ANPD001, has completed dosing of the first two cohorts in the world's first multi-center, multi-patient clinical trial using patient-specific iPSC-derived cell replacement.

He earned his PhD in Biomedical Engineering from Georgia Tech and Emory University and completed a postdoctoral fellowship at The Scripps Research Institute, where his work in patient specific dopamine neurons contributed to Aspen's founding.

Dr. Bratt Leal has led multidisciplinary R&D teams across discovery and preclinical development and is a recipient of the 2023 Biocom California Life Science Catalyst Award recognizing emerging leaders advancing human health.